{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Xu Y"],"pubmed_abstract":["<h4>Background</h4>Although CA19-9 is an essential blood biomarker of pancreatic cancer (PC), its sensitivity and specificity are limited for early detection.<h4>Methods</h4>We analyzed the serum proprotein convertase subtilisin/kexin type 9 (sPCSK9) in PC patients, benign disease groups (BDG), and healthy controls (HC) by ELISA.<h4>Results</h4>Consistently, sPCSK9 was considerably lower in PC patients than in HC (Z = -2.546, <i>P</i> < 0.05), and sPCSK9 in PC patients was statistically significantly higher than in BDG (Z = -5.457, <i>P</i> < 0.001). sPCSK9 was linked to the invasion of lymph nodes (χ<sup>2</sup> = 6.846, <i>P</i> < 0.01). According to ROC curves, combining sPCSK9 with CA19-9 could potentially enhance the diagnostic capability of CA19-9 in early-stage PC patients. Furtherm"],"journal":["PeerJ"],"pagination":["e18018"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11397121"],"repository":["biostudies-literature"],"pubmed_title":["Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer."],"pmcid":["PMC11397121"],"pubmed_authors":["Yang Y","Zhang Z","Xiong Q","Zhu Q","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"Serum PCSK9 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.","description":"<h4>Background</h4>Although CA19-9 is an essential blood biomarker of pancreatic cancer (PC), its sensitivity and specificity are limited for early detection.<h4>Methods</h4>We analyzed the serum proprotein convertase subtilisin/kexin type 9 (sPCSK9) in PC patients, benign disease groups (BDG), and healthy controls (HC) by ELISA.<h4>Results</h4>Consistently, sPCSK9 was considerably lower in PC patients than in HC (Z = -2.546, <i>P</i> < 0.05), and sPCSK9 in PC patients was statistically significantly higher than in BDG (Z = -5.457, <i>P</i> < 0.001). sPCSK9 was linked to the invasion of lymph nodes (χ<sup>2</sup> = 6.846, <i>P</i> < 0.01). According to ROC curves, combining sPCSK9 with CA19-9 could potentially enhance the diagnostic capability of CA19-9 in early-stage PC patients. Furtherm","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-06-03T20:36:51.237Z","creation":"2025-04-04T00:45:28.004Z"},"accession":"S-EPMC11397121","cross_references":{"pubmed":["39282119"],"doi":["10.7717/peerj.18018"]}}